A cancer diagnosis should trigger a plan, not a panic. Yet too often, men diagnosed with prostate cancer are pushed toward a decision before they fully understand what the disease threatens, what treatment can deliver, and what it may take away.
As a urologic oncologist, I believe we must stop treating survival as the only measure of success.
A treatment that controls cancer but leaves a man incontinent, sexually impaired, or burdened by consequences he never understood has not earned an unquestioned victory.
This is not a niche concern. The American Cancer Society estimates that 333,830 men in the United States will be diagnosed with prostate cancer in 2026, with 36,320 deaths projected.
Behind those figures are families confronting the same question: How do we fight a potentially deadly disease without causing avoidable harm?
The answer matters far beyond prostate cancer. Medicine must judge interventions by both what they prevent and what patients must live with afterward.
The Lasting Costs of Treatment
I have cared for men across decades of their lives. That perspective makes one fact impossible to ignore: a procedure may take hours, while its side effects can last for years.
Urinary incontinence can restrict work, travel, and ordinary social life. Erectile dysfunction can reshape intimacy and relationships.
These are not minor inconveniences or acceptable collateral damage to be mentioned in passing. They are outcomes that belong at the center of the treatment decision.
Fear, understandably, can drown out nuance. Patients may hear "cancer" and assume that immediate, maximal treatment is the only responsible response.
But prostate cancer varies widely. Some tumors demand prompt, intensive treatment. Others grow slowly, and men may live with them for years without the cancer becoming the main threat to their lives.
The task is to distinguish one situation from the other, not to treat every diagnosis as if it carries the same danger.
Research reinforces why treatment decisions must account for more than cancer control alone. In September 2026, the American College of Surgeons reported findings from a national analysis of more than 20,000 men with prostate cancer, followed for up to 20 years.
Surgery was associated with higher rates of urinary incontinence and erectile dysfunction, while radiation was associated with increased urinary complications and a 45% higher death rate from any cause during follow-up.
Researchers also observed higher all-cause mortality among men receiving radiation, although they could not determine whether treatment caused the difference.
The message is that prostate cancer treatments carry distinct risks, and patients need evidence-based discussions about their potential consequences before choosing a course of care.
Making Informed Choices About Care
Advances in MRI, targeted biopsy, and MRI-ultrasound fusion can help clinicians locate suspicious lesions more accurately.
For carefully selected men, focal therapies, including freezing, laser, electrical pulses, and focused ultrasound, aim to destroy targeted cancer while preserving more healthy tissue.
These approaches are not suitable for every tumor, and their long-term role continues to be studied. Surgery and radiation remain essential when cancer risk and extent warrant them.
Active surveillance is also a legitimate option for appropriate patients, provided it involves disciplined monitoring and clear criteria for action.
Imagine a healthcare system that makes cancer control, continence, sexual function, long-term well-being, and patient priorities part of every treatment conversation and measures those outcomes openly. Men could make informed choices that fit both their disease and their lives.
The alternative is a system that celebrates a technically successful procedure while leaving patients unprepared for lasting harm, or exposing them to treatment whose benefits they never fully understood.
We can do better, but good intentions are not enough. Physicians and hospital systems must report quality-of-life outcomes alongside recurrence and survival, and explain them in plain language.
Patients should ask how aggressive their cancer is, what monitoring involves, what each treatment is likely to achieve, which side effects may persist, and whether a second opinion could change their decision.
I welcome second opinions; a considered choice is not a challenge to a doctor’s authority. It is a patient exercising theirs and pursuing due diligence before a final decision.
The goal is to avoid treating patients blindly. We must match the intervention to the cancer, the person, and the evidence, and judge success by the life that follows, not merely by the disease we set out to defeat.
Dr. Fernando Bianco is a urologist and founder of Focalyx, a prostate imaging and focal-treatment company. All opinions are the author’s own.